UNSPSC 51172314: Pralidoxime

This classification denotes a cholinergic agonist with the molecular formula C7H9N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7MU9UTP52, chemically known as pyridinium, 2-((hydroxyimino)methyl)-1-methyl-, iodide but generally known as pralidoxime, which bears US NIH Compound Identifier 5353894. European Medicines Agency schedules Pralidoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04002MIG.

UNSPSC 51172314 Pralidoxime is a Commodity code capturing pharmaceutical products purchased by state and local health and human services agencies, criminal justice departments, and cooperative purchasing alliances. Recent solicitations show state and local governments buying pralidoxime and related pharmaceuticals through three distinct procurement models: direct specimen testing and laboratory services incorporating pharmaceutical screening (immunoassay and confirmatory testing), bulk generic multi-source pharmaceuticals distributed through authorized wholesalers to state facilities, and exploratory direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit manager intermediaries. The issuing bodies span state health and human services commissions, county criminal justice and community supervision departments, and multistate cooperative purchasing alliances serving state and local government members across multiple jurisdictions.

Activity centers in Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, requesting offender specimen collection and drug testing services including immunoassay screening with confirmatory LC/MS/MS or GC/MS analysis, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with optional three-year extension. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota, Oregon, and other participating jurisdictions, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors under the MMCAP RFP must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co.) and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.